Iteos Begin Period Cash Flow from 2010 to 2024
| ITOS Stock | USD 8.32 0.19 2.34% |
Begin Period Cash Flow | First Reported 2019-03-31 | Previous Quarter 146.6 M | Current Value 251.1 M | Quarterly Volatility 290.6 M |
Check Iteos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iteos Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 3.4 M, Net Interest Income of 32.4 M or Interest Income of 32.4 M, as well as many indicators such as Price To Sales Ratio of 32.65, Dividend Yield of 0.0 or PTB Ratio of 0.65. Iteos financial statements analysis is a perfect complement when working with Iteos Therapeutics Valuation or Volatility modules.
Iteos | Begin Period Cash Flow |
Latest Iteos Therapeutics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Iteos Therapeutics over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Iteos Therapeutics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Iteos Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Iteos Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 130,829,453 | |
| Geometric Mean | 42,816,552 | |
| Coefficient Of Variation | 175.86 | |
| Mean Deviation | 163,696,932 | |
| Median | 18,817,000 | |
| Standard Deviation | 230,077,441 | |
| Sample Variance | 52935.6T | |
| Range | 830M | |
| R-Value | 0.62 | |
| Mean Square Error | 35435.6T | |
| R-Squared | 0.38 | |
| Significance | 0.01 | |
| Slope | 31,647,366 | |
| Total Sum of Squares | 741098.8T |
Iteos Begin Period Cash Flow History
About Iteos Therapeutics Financial Statements
Iteos Therapeutics shareholders use historical fundamental indicators, such as Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Iteos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Iteos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Iteos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 285 M | 280.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.